BiotechTube
Home/Braveheart Bio/Emil deGoma, M.D.
ED

Emil deGoma, M.D.

Chief Medical Officer

Braveheart Bio

Therapeutic Areas

CardiovascularMetabolic

Braveheart Bio Pipeline

DrugIndicationPhase
BHB-1893Hypertrophic Cardiomyopathy (Obstructive and Non-obstructive)Phase 3

Leadership Team at Braveheart Bio

TM
Travis Murdoch, M.D.
Chief Executive Officer
MA
Michele Anderson
Chief Development Officer
ME
Marc Evanchik, M.S.
Chief Scientific Officer
PR
Paul Rickey
Chief Financial Officer
View full Braveheart Bio profile